Relay Therapeutics

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

News

RLAY

Relay Therapeutics shares are trading lower by 17.8% during Wednesday&#39;s session. The company priced its $200 million offering.

Why Relay Therapeutics (RLAY) Stock Is Down 17% Today

analyst ratings image

Downgrades

Markets

Analyst Ratings

Trading Ideas

ACET

ANIP

SUPN

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday

GameStopPre-market: 5 titoli da monitorare oggi, 10 settembre 2024

Pre-Market Outlook

Movers

EVGO

WOOF

GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Relay Therapeutics Inc

Earnings

Press Releases

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Participate in Upcoming Investor Conferences

Health Care

General

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Abivax

Altimmune

AnaptysBio

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Chimerix

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Kura Oncology

LENZ Therapeutics

MeiraGTx Hldgs

Opthea Limited - American Depositary Shares

Opthea

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sana Biotechnology

Sionna Therapeutics

Tyra Biosciences

Valneva

Verve Therapeutics

Goldman Sachs

Stifel

HC Wainwright & Co.

JMP Securities

Leerink Partners

Comments

Relay Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga